StockData
First Tracks Biotherapeutics, Inc. logo

First Tracks Biotherapeutics, Inc. (TRAX) stock

TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026
$43.57−2.99 (-6.42%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

First Tracks Biotherapeutics cash

Cash and short-term investments held at the end of each period.

First Tracks Biotherapeutics's cash was $155.63M at Sep 30, 2026. For fiscal 2025 it was $311.64M, up 153.2% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$311.64M+153.2%
FY2024Dec 31, 2024$123.08M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$155.63M+41.7%
Q2 FY2026Jun 30, 2026$168.02M+279.3%
Q1 FY2026Mar 31, 2026$286.46M+190.4%
Q4 FY2025Dec 31, 2025$311.64M+153.2%
Q3 FY2025Sep 30, 2025$109.83M–
Q2 FY2025Jun 30, 2025$44.30M–
Q1 FY2025Mar 31, 2025$98.64M–
Q4 FY2024Dec 31, 2024$123.08M–

More First Tracks Biotherapeutics figures

See a number that looks wrong?